Client News

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

Progress in Clinical Development for Alzheimer´s and Other Indications: Galimedix Therapeutics Successfully Completes Phase 1 Study With Oral Small Molecule, GAL-101, an Amyloid Beta Aggregation Modulator

AFYREN Announces its 2025 Half-Year Financial Results

ARTCLINE Announces Closing of €5 Million Financing

Abivax Presents First Half 2025 Financial Results

Newron to Present Data and Updates on its Clinical Program Evaluating Evenamide as an Add-on Treatment for Schizophrenia at the 2025 World Congress of Biological Psychiatry (WCBP)

Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025

AL-S Pharma Announces Positive Topline Results from Phase 2 Study of AP-101 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline

Healthtech Venture Studio M2care Raises €26 Million to Accelerate the Creation and Development of Innovative Healthcare Projects